Skip to main content

Trevi Therapeutics, Inc.

corporate_fare Company Profile

Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed TRVI - Latest Insights

TRVI
Apr 21, 2026, 4:00 PM EDT
Filing Type: DEF 14A
Importance Score:
8
TRVI
Apr 20, 2026, 4:18 PM EDT
Source: Reuters
Importance Score:
8
TRVI
Apr 17, 2026, 4:17 PM EDT
Filing Type: 424B5
Importance Score:
8
TRVI
Apr 17, 2026, 8:06 AM EDT
Filing Type: 8-K
Importance Score:
8
TRVI
Apr 16, 2026, 10:42 PM EDT
Source: Reuters
Importance Score:
8
TRVI
Apr 16, 2026, 4:16 PM EDT
Filing Type: 424B5
Importance Score:
8
TRVI
Apr 16, 2026, 4:10 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
TRVI
Apr 10, 2026, 4:32 PM EDT
Filing Type: PRE 14A
Importance Score:
8
TRVI
Mar 17, 2026, 4:08 PM EDT
Filing Type: 10-K
Importance Score:
8
TRVI
Mar 17, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
8
TRVI
Mar 17, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
TRVI
Mar 09, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
9